-
Something wrong with this record ?
Tazemetostat in the therapy of pediatric INI1-negative malignant rhabdoid tumors
K. Vejmelkova, P. Pokorna, K. Noskova, A. Faustmannova, K. Drabova, Z. Pavelka, V. Bajciova, M. Broz, P. Tinka, M. Jezova, H. Palova, L. Kren, D. Valik, O. Slaby, J. Sterba
Language English Country England, Great Britain
Document type Journal Article
Grant support
NU20-03-00240
Ministry of Health of the Czech Republic
NU20-03-00240
Ministry of Health of the Czech Republic
NU20-03-00240
Ministry of Health of the Czech Republic
NU20-03-00240
Ministry of Health of the Czech Republic
NU20-03-00240
Ministry of Health of the Czech Republic
NU20-03-00240
Ministry of Health of the Czech Republic
NU20-03-00240
Ministry of Health of the Czech Republic
NU20-03-00240
Ministry of Health of the Czech Republic
FNBr, 65269705
Ministry of Health of the Czech Republic - DRO
FNBr, 65269705
Ministry of Health of the Czech Republic - DRO
FNBr, 65269705
Ministry of Health of the Czech Republic - DRO
FNBr, 65269705
Ministry of Health of the Czech Republic - DRO
FNBr, 65269705
Ministry of Health of the Czech Republic - DRO
FNBr, 65269705
Ministry of Health of the Czech Republic - DRO
MUNI/A/1395/2022
Specific University Research provided by MEYS
MUNI/A/1395/2022
Specific University Research provided by MEYS
MUNI/A/1395/2022
Specific University Research provided by MEYS
MUNI/A/1395/2022
Specific University Research provided by MEYS
LX22NPO5102
National Institute for Cancer Research (Programme EXCELES)
LX22NPO5102
National Institute for Cancer Research (Programme EXCELES)
LX22NPO5102
National Institute for Cancer Research (Programme EXCELES)
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
Nature Open Access
from 2011-12-01
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Health & Medicine (ProQuest)
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
Springer Nature OA/Free Journals
from 2011-12-01
- MeSH
- Child MeSH
- DNA Helicases MeSH
- SMARCB1 Protein MeSH
- Nuclear Proteins MeSH
- Infant MeSH
- Humans MeSH
- Neoplasm Recurrence, Local drug therapy MeSH
- Central Nervous System Neoplasms * pathology MeSH
- Child, Preschool MeSH
- Rhabdoid Tumor * drug therapy pathology MeSH
- Teratoma * pathology MeSH
- Transcription Factors MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Rhabdoid tumors are aggressive tumors that may arise in the kidney, soft tissue, central nervous system, or other organs. They are defined by SMARCB1 (INI1) or SMARCA4 alterations. Often, very young children are affected, and the prognosis is dismal. Four patients with primary atypical teratoid rhabdoid tumor (AT/RT, a rhabdoid tumor in the central nervous system) were treated by resection and high dose chemotherapy. Tazemetostat was introduced after completion of chemotherapy. Three patients have achieved an event free survival of 32, 34, and 30 months respectively. One progressed and died. His overall survival was 20 months. One patient was treated for a relapsed atypical teratoid rhabdoid tumor. The treatment combined metronomic therapy, radiotherapy, tazemetostat and immunotherapy. This patient died of disease progression, with an overall survival of 37 months. One patient was treated for a rhabdoid tumor of the ovary. Tazemetostat was given as maintenance after resection, chemotherapy, and radiotherapy, concomitantly with immunotherapy. Her event free survival is 44 months. Only approximately 40% of patients with rhabdoid tumors achieve long-term survival. Nearly all relapses occur within two years from diagnosis. The event free survival of four of the six patients in our cohort has exceeded this timepoint. Tazemetostat has been mostly tested as a single agent in the relapsed setting. We present promising results when applied as maintenance or add on in the first line treatment.
Department of Pharmacology and Toxicology Faculty of Pharmacy Masaryk University 62500 Brno Czechia
Department of Pharmacology Faculty of Medicine Masaryk University 62500 Brno Czechia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000283
- 003
- CZ-PrNML
- 005
- 20240321094912.0
- 007
- ta
- 008
- 240109s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-023-48774-2 $2 doi
- 035 __
- $a (PubMed)38062114
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vejmelkova, Klara $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 62500, Brno, Czechia. vejmelkova.klara@fnbrno.cz
- 245 10
- $a Tazemetostat in the therapy of pediatric INI1-negative malignant rhabdoid tumors / $c K. Vejmelkova, P. Pokorna, K. Noskova, A. Faustmannova, K. Drabova, Z. Pavelka, V. Bajciova, M. Broz, P. Tinka, M. Jezova, H. Palova, L. Kren, D. Valik, O. Slaby, J. Sterba
- 520 9_
- $a Rhabdoid tumors are aggressive tumors that may arise in the kidney, soft tissue, central nervous system, or other organs. They are defined by SMARCB1 (INI1) or SMARCA4 alterations. Often, very young children are affected, and the prognosis is dismal. Four patients with primary atypical teratoid rhabdoid tumor (AT/RT, a rhabdoid tumor in the central nervous system) were treated by resection and high dose chemotherapy. Tazemetostat was introduced after completion of chemotherapy. Three patients have achieved an event free survival of 32, 34, and 30 months respectively. One progressed and died. His overall survival was 20 months. One patient was treated for a relapsed atypical teratoid rhabdoid tumor. The treatment combined metronomic therapy, radiotherapy, tazemetostat and immunotherapy. This patient died of disease progression, with an overall survival of 37 months. One patient was treated for a rhabdoid tumor of the ovary. Tazemetostat was given as maintenance after resection, chemotherapy, and radiotherapy, concomitantly with immunotherapy. Her event free survival is 44 months. Only approximately 40% of patients with rhabdoid tumors achieve long-term survival. Nearly all relapses occur within two years from diagnosis. The event free survival of four of the six patients in our cohort has exceeded this timepoint. Tazemetostat has been mostly tested as a single agent in the relapsed setting. We present promising results when applied as maintenance or add on in the first line treatment.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a předškolní dítě $7 D002675
- 650 12
- $a rhabdoidní nádor $x farmakoterapie $x patologie $7 D018335
- 650 _2
- $a lokální recidiva nádoru $x farmakoterapie $7 D009364
- 650 _2
- $a gen SMARCB1 $7 D000071796
- 650 12
- $a teratom $x patologie $7 D013724
- 650 12
- $a nádory centrálního nervového systému $x patologie $7 D016543
- 650 _2
- $a DNA-helikasy $7 D004265
- 650 _2
- $a jaderné proteiny $7 D009687
- 650 _2
- $a transkripční faktory $7 D014157
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pokorna, Petra $u Department of Biology, Faculty of Medicine and Central European Institute of Technology, Masaryk University, 62500, Brno, Czechia
- 700 1_
- $a Noskova, Kristyna $u Department of Hospital Pharmacy, University Hospital Brno and Faculty of Medicine, Masaryk University, 62500, Brno, Czechia $u Department of Pharmacology, Faculty of Medicine, Masaryk University, 62500, Brno, Czechia
- 700 1_
- $a Faustmannova, Anna $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, 62500, Brno, Czechia
- 700 1_
- $a Drabova, Klara $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 62500, Brno, Czechia
- 700 1_
- $a Pavelka, Zdenek $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 62500, Brno, Czechia
- 700 1_
- $a Bajciova, Viera $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 62500, Brno, Czechia
- 700 1_
- $a Broz, Martin $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 62500, Brno, Czechia
- 700 1_
- $a Tinka, Pavel $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 62500, Brno, Czechia $7 xx0315268
- 700 1_
- $a Jezova, Marta $u Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, 62500, Czechia
- 700 1_
- $a Palova, Hana $u Department of Biology, Faculty of Medicine and Central European Institute of Technology, Masaryk University, 62500, Brno, Czechia
- 700 1_
- $a Kren, Leos $u Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, 62500, Czechia
- 700 1_
- $a Valik, Dalibor $u Department of Laboratory Medicine, University Hospital Brno and Department of Laboratory Methods, Faculty of Medicine, Masaryk University, 62500, Brno, Czechia
- 700 1_
- $a Slaby, Ondrej $u Department of Biology, Faculty of Medicine and Central European Institute of Technology, Masaryk University, 62500, Brno, Czechia
- 700 1_
- $a Sterba, Jaroslav $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 62500, Brno, Czechia
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 13, č. 1 (2023), s. 21623
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38062114 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240321094906 $b ABA008
- 999 __
- $a ok $b bmc $g 2049131 $s 1209977
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 13 $c 1 $d 21623 $e 20231207 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- GRA __
- $a NU20-03-00240 $p Ministry of Health of the Czech Republic
- GRA __
- $a NU20-03-00240 $p Ministry of Health of the Czech Republic
- GRA __
- $a NU20-03-00240 $p Ministry of Health of the Czech Republic
- GRA __
- $a NU20-03-00240 $p Ministry of Health of the Czech Republic
- GRA __
- $a NU20-03-00240 $p Ministry of Health of the Czech Republic
- GRA __
- $a NU20-03-00240 $p Ministry of Health of the Czech Republic
- GRA __
- $a NU20-03-00240 $p Ministry of Health of the Czech Republic
- GRA __
- $a NU20-03-00240 $p Ministry of Health of the Czech Republic
- GRA __
- $a FNBr, 65269705 $p Ministry of Health of the Czech Republic - DRO
- GRA __
- $a FNBr, 65269705 $p Ministry of Health of the Czech Republic - DRO
- GRA __
- $a FNBr, 65269705 $p Ministry of Health of the Czech Republic - DRO
- GRA __
- $a FNBr, 65269705 $p Ministry of Health of the Czech Republic - DRO
- GRA __
- $a FNBr, 65269705 $p Ministry of Health of the Czech Republic - DRO
- GRA __
- $a FNBr, 65269705 $p Ministry of Health of the Czech Republic - DRO
- GRA __
- $a MUNI/A/1395/2022 $p Specific University Research provided by MEYS
- GRA __
- $a MUNI/A/1395/2022 $p Specific University Research provided by MEYS
- GRA __
- $a MUNI/A/1395/2022 $p Specific University Research provided by MEYS
- GRA __
- $a MUNI/A/1395/2022 $p Specific University Research provided by MEYS
- GRA __
- $a LX22NPO5102 $p National Institute for Cancer Research (Programme EXCELES)
- GRA __
- $a LX22NPO5102 $p National Institute for Cancer Research (Programme EXCELES)
- GRA __
- $a LX22NPO5102 $p National Institute for Cancer Research (Programme EXCELES)
- LZP __
- $a Pubmed-20240109
